SCHEDULE: Soleus Capital Discloses 7.6% Stake in NovoCure

Soleus Capital Master Fund and related entities have disclosed a 7.6% beneficial ownership stake in NovoCure Limited, totaling 8,530,665 ordinary shares.

Summary

• Soleus Capital Master Fund, L.P., along with its affiliated entities Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, L.P., Soleus GP, LLC, and Guy Levy, collectively reported beneficial ownership of 8,530,665 ordinary shares of NovoCure Limited.
• This aggregate amount represents 7.6% of NovoCure Limited's outstanding ordinary shares.
• The percentage is calculated based on 111,981,981 ordinary shares outstanding as of October 24, 2025, as reported in NovoCure's Form 10-Q filed on October 30, 2025.
• The reporting persons hold shared voting and shared dispositive power over all 8,530,665 shares.
• The filing certifies that the securities were not acquired or held for the purpose of changing or influencing the control of NovoCure Limited.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a significant institutional stake (7.6%) by Soleus Capital suggests a degree of confidence in NovoCure Limited, although the filing itself is purely a disclosure of ownership.

Industry Context

StockSavvy.ai notes that institutional ownership disclosures like this Schedule 13G provide transparency into significant investor positions, which can sometimes signal confidence or strategic interest in a company within its sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant institutional ownership, potentially influencing market perception and trading activity.

Key Dates

Keywords

NovoCure Limited, Soleus Capital, Beneficial Ownership, SEC Filing, Institutional Investor, Equity Stake, G6674U108